AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17728422 — intervention group
Group type: COMPARATOR
Intervention: Untreated control subjects
Number of subjects: 168
Study 15499897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccination (4 microg)
Number of subjects: 143
Study 15499897 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccination (20 microg)
Number of subjects: 143
Study 11181776 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2)
Number of subjects: 3488
Study 11181776 — intervention group
Group type: EXPERIMENTAL
Intervention: Single repeat cytology with HSIL threshold
Number of subjects: 3488
Study 11181776 — intervention group
Group type: EXPERIMENTAL
Intervention: Single repeat cytology with ASCUS threshold
Number of subjects: 3488
Study 11181776 — intervention group
Group type: COMPARATOR
Intervention: Immediate colposcopy (reference standard)
Number of subjects: 3488
Study 9820611 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO) at a flow rate of 6000 IU per week (36 IU/h)
Number of subjects: 5
Study 9820611 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO)
Number of subjects: 5
Study 9820611 — intervention group
Group type: COMPARATOR
Intervention: Weekly bolus subcutaneous injection of recombinant human erythropoietin (rhEPO) at a dose of 6000 IU
Number of subjects: 5
Study 8584530 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 0.2 mg (test effect)
Number of subjects: 15
Study 8584530 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 0.2 mg, salbutamol 0.2 mg, salmeterol 0.05 mg (best effect)
Number of subjects: 15
Study 8584530 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 2‐agonist (TGV reduction)
Number of subjects: 15
Study 2196261 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 2196261 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0
Study 159067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl as part of the anaesthetic technique
Number of subjects: 0
Study 159067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 0
Study 31369510 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pharyngeal fat grafting
Number of subjects: 167
Study 30842028 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor with alarms activated after 6 months
Number of subjects: 907
Study 30842028 — intervention group
Group type: COMPARATOR
Intervention: Control group (alarms deactivated)
Number of subjects: 907
Study 27602992 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and therapist-guided internet intervention based on solution-focused and cognitive-behavioral therapy
Number of subjects: 39
Study 27602992 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study 26052657 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 597
Study 26052657 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 597
Study 26052657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 597
Study 26052657 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 597
Study 26052657 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregate Housing (CONG)
Number of subjects: 597
Study 23558871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (Group 1, n = 60) - 80 mg daily aspirin orally and 5000 U unfractionated heparin per 8 h subcutaneously from admission to discharge.
Number of subjects: 120
Study 23558871 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Group 2, n = 60) - same dose of heparin alone.
Number of subjects: 120
Study 23558871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (Group 1)
Number of subjects: 120
Study 23558871 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Group 2)
Number of subjects: 120
Study 23558871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 20130074 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening group
Number of subjects: 4562
Study 20130074 — intervention group
Group type: COMPARATOR
Intervention: Case-finding group
Number of subjects: 4562
Study 19001832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored face-to-face counseling
Number of subjects: 0
Study 19001832 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone counseling
Number of subjects: 0
Study 19001832 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tailored feedback
Number of subjects: 0
Study 19001832 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based health behavior assessment with feedback and education
Number of subjects: 0
Study 19001832 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in general
Number of subjects: 0
Study 16157399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 255
Study 16157399 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg od
Number of subjects: 255
Study 16157399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 255
Study 16157399 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 255
Study 12636943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeved cytobrush
Number of subjects: 62
Study 12636943 — intervention group
Group type: COMPARATOR
Intervention: Endocervical curette
Number of subjects: 62
Study 11192711 — intervention group
Group type: EXPERIMENTAL
Intervention: E5510 (4 mg x day(-1))
Number of subjects: 15
Study 11192711 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-thrombotic medication)
Number of subjects: 15
Study 8642829 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐stat management during cardiopulmonary bypass
Number of subjects: 70
Study 8642829 — intervention group
Group type: COMPARATOR
Intervention: alpha‐stat management during cardiopulmonary bypass
Number of subjects: 70
Study 1686581 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart)
Number of subjects: 6
Study 1686581 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart) after ranitidine 300 mg (administered 1-2 hours prior)
Number of subjects: 6
Study 1686581 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg (as hydrochloride salt)
Number of subjects: 6
Study 6383993 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase preparation containing levonorgestrel
Number of subjects: 0
Study 6383993 — intervention group
Group type: COMPARATOR
Intervention: Monophasic combination preparations (levonorgestrel and desogestrel)
Number of subjects: 0
Study 31740476 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBTI via a Smartphone application
Number of subjects: 200
Study 31740476 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study 29775985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training (SMT)
Number of subjects: 43
Study 29775985 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 43
Study 29775985 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 43
Study 27955688 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil PCA
Number of subjects: 400
Study 27955688 — intervention group
Group type: COMPARATOR
Intervention: Pethidine intramuscular injection
Number of subjects: 400
Study 24773166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.5 mg/d
Number of subjects: 77
Study 24773166 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 200 mg/d
Number of subjects: 77
Study 22932119 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lixivaptan once daily, titrated to 25-100 mg once daily depending on serum sodium concentration
Number of subjects: 106
Study 22932119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 20178636 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), 3 sessions per week for up to 6 weeks, total up to 18 sessions.
Number of subjects: 132
Study 20178636 — intervention group
Group type: COMPARATOR
Intervention: Algorithm-based pharmacological treatment as usual.
Number of subjects: 132
Study 17632760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (Impact) for 5 days preoperatively
Number of subjects: 46
Study 17632760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (Impact enriched with glycine) for 2 days preoperatively
Number of subjects: 46
Study 17632760 — intervention group
Group type: COMPARATOR
Intervention: Control group (Impact for 7 days postoperatively, no preoperative treatment)
Number of subjects: 46
Study 16547345 — intervention group
Group type: COMPARATOR
Intervention: Preoperative fMRI session with verbal task
Number of subjects: 24
Study 16547345 — intervention group
Group type: COMPARATOR
Intervention: Preoperative fMRI session with nonverbal task
Number of subjects: 24
Study 16547345 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fMRI session in left TLE patients
Number of subjects: 24
Study 15575124 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU)
Number of subjects: 254
Study 15575124 — intervention group
Group type: COMPARATOR
Intervention: Medical Wards (MW)
Number of subjects: 254
Study 10606838 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (mean dose: 550 mg day‐1, range: 400‐1000 mg day‐1)
Number of subjects: 12
Study 9180105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) for 36 to 48 hours
Number of subjects: 437
Study 9180105 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 437
Study 7902024 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice‐daily levocabastine
Number of subjects: 128
Study 7902024 — intervention group
Group type: COMPARATOR
Intervention: Twice‐daily oral terfenadine
Number of subjects: 128
Study 3895384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for 4 weeks
Number of subjects: 100
Study 3895384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30626209 — intervention group
Group type: EXPERIMENTAL
Intervention: AD group (3-minute freeze cycles added), n=55
Number of subjects: 110
Study 30626209 — intervention group
Group type: COMPARATOR
Intervention: Non-AD group (no additional freeze cycles), n=55
Number of subjects: 110
Study 26898720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL)
Number of subjects: 360
Study 26898720 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid tablets (IFA)
Number of subjects: 360
Study 25039804 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 98
Study 25039804 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed DHA-treated infants
Number of subjects: 98
Study 25039804 — intervention group
Group type: COMPARATOR
Intervention: Control group (formula-fed infants)
Number of subjects: 98
Study 25905139 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session psychoeducational program for couples
Number of subjects: 169
Study 22057607 — intervention group
Group type: EXPERIMENTAL
Intervention: Jeopardy game format
Number of subjects: 82
Study 22057607 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture format
Number of subjects: 82
Study 19414665 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab (5 mg/kg every 2 weeks x 26)
Number of subjects: 2710
Study 19414665 — intervention group
Group type: COMPARATOR
Intervention: modified FOLFOX6
Number of subjects: 2710
Study 19414665 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab
Number of subjects: 2710
Study 17707751 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with aspirin and clopidogrel)
Number of subjects: 274
Study 15031791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal delivery of canarypox virus vaccine (vCP 205)
Number of subjects: 84
Study 15031791 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic delivery of canarypox virus vaccine (vCP 205)
Number of subjects: 84
Study 15031791 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic delivery of rabies vaccine (subunit rabies vaccine)
Number of subjects: 84
Study 15031791 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic delivery of HIV-1 MN recombinant glycoprotein (rgp) 120
Number of subjects: 84
Study 11803987 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide strip‐based bleaching system
Number of subjects: 20
Study 11803987 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide gel in a stock tray with anticavity whitening dentifrice and after‐bleaching whitening mouthrinse
Number of subjects: 20
Study 9569475 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria toxoid and tetanus toxoid conjugates
Number of subjects: 0
Study 9569475 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 0
Study 9569475 — intervention group
Group type: COMPARATOR
Intervention: PncOMPC
Number of subjects: 0
Study 7826493 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 100 mg
Number of subjects: 29
Study 7826493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7826493 — intervention group
Group type: COMPARATOR
Intervention: GM1 or Placebo
Number of subjects: 29
Study 2905251 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 12
Study 2905251 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31190497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with rehabilitation intervention
Number of subjects: 70
Study 31190497 — intervention group
Group type: COMPARATOR
Intervention: Simple conventional rehabilitation intervention
Number of subjects: 70
Study 28279484 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg per day)
Number of subjects: 253
Study 28279484 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (0.5 mg/kg per day)
Number of subjects: 253
Study 28279484 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 253
Study 28279484 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 253
Study 26164786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/valsartan 80 mg (L10/V80)
Number of subjects: 497
Study 26164786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/valsartan 160 mg (L10/V160)
Number of subjects: 497
Study 26164786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 20 mg/valsartan 160 mg (L20/V160)
Number of subjects: 497
Study 26164786 — intervention group
Group type: COMPARATOR
Intervention: Lercanidipine 10 mg (L10)
Number of subjects: 497
Study 23509239 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention
Number of subjects: 228186
Study 21641636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to oxaliplatin and fluoropyrimidine chemotherapy (arm B)
Number of subjects: 1630
Study 21641636 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin and fluoropyrimidine chemotherapy alone (arm A)
Number of subjects: 1630
Study 19209478 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust manipulation plus electro-thermal therapy for 5 treatment sessions
Number of subjects: 45
Study 19209478 — intervention group
Group type: COMPARATOR
Intervention: Electro-thermal therapy for 5 treatment sessions
Number of subjects: 45
Study 16416224 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole, 40 mg
Number of subjects: 36
Study 16416224 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole, 20 mg
Number of subjects: 36
Study 16416224 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 14960678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining prosthesis
Number of subjects: 20
Study 14960678 — intervention group
Group type: COMPARATOR
Intervention: Posterior stabilized prosthesis
Number of subjects: 20
Study 12625581 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox FreeHands HME with multi-magnet automatic speaking valve (ASV)
Number of subjects: 20
Study 12625581 — intervention group
Group type: COMPARATOR
Intervention: Regular ASV
Number of subjects: 20
Study 11156096 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 microg/kg
Number of subjects: 60
Study 11156096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9366668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant exchange (second implant)
Number of subjects: 15
Study 9366668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant exchange (third implant)
Number of subjects: 15
Study 1567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of automaticity, regimen, self‐control, and social skills training
Number of subjects: 0
Study 1567339 — intervention group
Group type: COMPARATOR
Intervention: Automaticity, regimen, self‐control, and social skills training (individually)
Number of subjects: 0
Study 3895098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT: plus allogeneic Neuraminidase‐treated blasts in high dosage)
Number of subjects: 102
Study 3895098 — intervention group
Group type: COMPARATOR
Intervention: Cyclic chemotherapy (CT) alone
Number of subjects: 102
Study 3895098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT) for patients receiving more than 2 cycles of maintenance therapy
Number of subjects: 102
Study 31102623 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-Bx
Number of subjects: 1140
Study 31102623 — intervention group
Group type: COMPARATOR
Intervention: TRUS-Bx
Number of subjects: 1140
Study 27704208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity high-speed power training (HSPT) for 12 weeks
Number of subjects: 42
Study 27704208 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity HSPT
Number of subjects: 42
Study 27704208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity HSPT
Number of subjects: 42
Study 27704208 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study 24886191 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (interchangeable diets: CSIRO, South Beach, Mediterranean)
Number of subjects: 144
Study 24886191 — intervention group
Group type: COMPARATOR
Intervention: No Choice group (set diet: CSIRO)
Number of subjects: 144
Study 22542465 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups (RMC)
Number of subjects: 480
Study 22542465 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 480
Study 22542465 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 480
Study 20154337 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan on top of other anti-hypertensive drugs (n = 47)
Number of subjects: 97
Study 20154337 — intervention group
Group type: COMPARATOR
Intervention: Other anti-hypertensive drugs alone (n = 50)
Number of subjects: 97
Study 18772641 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 0
Study 18772641 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 800 mg 3 times daily
Number of subjects: 0
Study 18772641 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 0
Study 15715535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual placental delivery + exteriorized uterine repair
Number of subjects: 840
Study 15715535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual placental delivery + in situ uterine repair
Number of subjects: 840
Study 15715535 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous placental delivery + exteriorized uterine repair
Number of subjects: 840
Study 15715535 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous placental delivery + in situ uterine repair
Number of subjects: 840
Study 15715535 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal groups (groups 1 and 3)
Number of subjects: 840
Study 15715535 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous groups (groups 2 and 4)
Number of subjects: 840
Study 14870884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate solution (25 mmol/L bicarbonate and either 10 or 15 mmol/L lactate)
Number of subjects: 0
Study 14870884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate 35 mmol/L
Number of subjects: 0
Study 14870884 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calcium (1.75 mmol/L) lactate/bicarbonate solution
Number of subjects: 0
Study 14870884 — intervention group
Group type: EXPERIMENTAL
Intervention: Product use questionnaire
Number of subjects: 0
Study 14870884 — intervention group
Group type: COMPARATOR
Intervention: Standard lactate solutions (35 or 40 mmol/L)
Number of subjects: 0
Study 15251661 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐D 31‐gauge, 8‐mm pen needles
Number of subjects: 50
Study 15251661 — intervention group
Group type: COMPARATOR
Intervention: B‐D conventional 30‐gauge, 8‐mm pen needles
Number of subjects: 50
Study 15251661 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin doses greater than 30 units
Number of subjects: 50
Study 15251661 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle retention time
Number of subjects: 50
Study 7626858 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 0
Study 7626858 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose chemotherapy
Number of subjects: 0
Study 1773272 — intervention group
Group type: COMPARATOR
Intervention: 3 fractions per week (3F/wk) radiotherapy
Number of subjects: 734
Study 1773272 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 fractions per week (5F/wk) radiotherapy
Number of subjects: 734